We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
- Authors
INZINGER, Martin; WIPPEL-SLUPETZKY, Katharina; WEGER, Wolfgang; RICHTER, Leo; MLYNEK, Alexander; FLEISCHANDERL, Barbara; SCHEURECKER, Christine; SANDOR, Nicolaus; MAIRHOFER, Daniela; SATOR, Paul G.; MOSER-OBERTHALER, Sabine; HÄRING, Nina; VIZNEROVA, Petra; PAINSI, Clemens; TANEW, Adrian; PONHOLZER, Peter; TATARSKI, Rafaella; BRENNER, Wilhelm; STINGL, Georg; SALMHOFER, Wolfgang
- Abstract
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p = 2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.
- Subjects
PSORIASIS treatment; DRUG efficacy; TUMOR necrosis factors; ADALIMUMAB; INFLIXIMAB; ETANERCEPT
- Publication
Acta Dermato-Venereologica, 2016, Vol 96, Issue 2, p207
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/00015555-2214